AR059206A1 - Uso de derivados de 4-imidazol para trastornos del snc - Google Patents
Uso de derivados de 4-imidazol para trastornos del sncInfo
- Publication number
- AR059206A1 AR059206A1 ARP070100342A ARP070100342A AR059206A1 AR 059206 A1 AR059206 A1 AR 059206A1 AR P070100342 A ARP070100342 A AR P070100342A AR P070100342 A ARP070100342 A AR P070100342A AR 059206 A1 AR059206 A1 AR 059206A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- phenyl
- lower alkyl
- halogen
- lower alkoxy
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 230000036760 body temperature Effects 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000013632 homeostatic process Effects 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 hydroxy, phenyl Chemical group 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere al uso de compuestos de la formula (1) en la que R es hidrogeno, halogeno, alquilo inferior, alcoxi inferior, hidroxi, fenilo, 5-fenilo u O-fenilo, que están opcionalmente sustituidos por alcoxi inferior o halogeno, o es benciloxi, C(O)O- alquilo inferior, cicloalquilo, o es alquilo inferior o alcoxi inferior sustituido por halogeno; Ar es arilo o heteroariio, elegidos entre el grupo formado por fenilo, naftilo, piridinilo, benzofuranilo, dihidrobenzofuranilo y pirazol; R1 y R1' con independencia entre si son hidrogeno, hidroxi, alquilo inferior, alcoxi inferior, o son fenilo o bencilo, que están opcionalmente sustituidos por halogeno; R2 es hidrogeno o alquilo inferior; n es el numero 1, 2, 3 o 4; y a sus sales farmacéuticamente activas, mezclas racémicas, enantiomeros, isomeros opticos y formas tautomeras, para la fabricacion de medicamentos destinados al tratamiento de la depresion, trastornos de ansiedad, trastorno bipolar, trastorno de hiperactividad con déficit de atencion, trastornos relacionados con el estrés, trastornos sicoticos, por ejemplo la esquizofrenia, enfermedades neurologicas, por ejemplo la enfermedad de Parkinson, trastornos neurodegenerativos, por ejemplo la enfermedad de Alzheimer, epilepsia, migrana, hipertension, abuso de fármacos y trastornos metabolicos, por ejemplo trastornos de ingestion de comida, diabetes, complicaciones diabéticas, obesidad, dislipidemia, trastornos de consumo y asimilacion de energía, trastornos y malfuncion de la temperatura corporal, homeostasis, trastornos de sueno, de ritmo circadiano y trastornos cardiovasculares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06100938 | 2006-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059206A1 true AR059206A1 (es) | 2008-03-19 |
Family
ID=38051581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100342A AR059206A1 (es) | 2006-01-27 | 2007-01-26 | Uso de derivados de 4-imidazol para trastornos del snc |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8158668B2 (es) |
| EP (1) | EP1981880B1 (es) |
| JP (1) | JP2009524616A (es) |
| KR (1) | KR101079914B1 (es) |
| CN (1) | CN101374832B (es) |
| AR (1) | AR059206A1 (es) |
| AT (1) | ATE458732T1 (es) |
| AU (1) | AU2007209380B2 (es) |
| BR (1) | BRPI0706759A2 (es) |
| CA (1) | CA2637308C (es) |
| DE (1) | DE602007004949D1 (es) |
| ES (1) | ES2338716T3 (es) |
| IL (1) | IL192885A0 (es) |
| NO (1) | NO20083356L (es) |
| RU (1) | RU2008130448A (es) |
| TW (1) | TW200738645A (es) |
| WO (1) | WO2007085556A2 (es) |
| ZA (1) | ZA200806457B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007209381A1 (en) | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of substituted 2-imidazole of imidazoline derivatives |
| AU2007312390B2 (en) * | 2006-10-19 | 2013-03-28 | F. Hoffmann-La Roche Ag | Aminomethyl-4-imidazoles |
| EP2114906B1 (en) | 2007-02-02 | 2014-08-06 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands for cns disorders |
| MX2009008777A (es) | 2007-02-13 | 2009-08-25 | Schering Corp | Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
| WO2008100480A1 (en) * | 2007-02-13 | 2008-08-21 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
| EP2125749A2 (en) | 2007-02-13 | 2009-12-02 | Schering Corporation | Functionally selective alpha2c adrenoreceptor agonists |
| AU2008270444A1 (en) | 2007-07-03 | 2009-01-08 | F. Hoffmann-La Roche Ag | 4-imidazolines and their use as antidepressants |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| AU2009205539B2 (en) * | 2008-01-18 | 2013-12-05 | Allergan.Inc | Substitued-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| RU2513086C2 (ru) * | 2008-07-24 | 2014-04-20 | Ф.Хоффманн-Ля Рош Аг | Производные 4,5-дигидро-оксазол-2-ила |
| AU2010289703A1 (en) * | 2009-08-26 | 2012-04-12 | Allergan, Inc. | Method of treating compulsive disorders with alpha-2B adrenergic receptor agonists |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| AR090557A1 (es) | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| EP2970240B1 (en) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| CA2924233C (en) * | 2013-10-07 | 2018-10-23 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
| KR101827980B1 (ko) | 2013-10-07 | 2018-02-13 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법 |
| BR112016006848A2 (pt) | 2013-10-07 | 2017-08-01 | Teikoku Pharma Usa Inc | métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina |
| CN103664788B (zh) * | 2013-12-04 | 2015-11-25 | 湖北生物医药产业技术研究院有限公司 | 制备美托咪啶的方法 |
| EP3411375B1 (en) | 2016-02-04 | 2020-08-05 | Chiesi Farmaceutici S.p.A. | Pyrazole derivatives as phosphoinositide 3-kinases inhibitors |
| WO2017157873A1 (en) | 2016-03-17 | 2017-09-21 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar |
| CN105884691B (zh) * | 2016-06-02 | 2017-08-25 | 江苏恒瑞医药股份有限公司 | 一种制备右美托咪定及其中间体的方法 |
| TWI764951B (zh) | 2016-10-31 | 2022-05-21 | 美商帝國製藥美國股份有限公司 | 用於處理疼痛之右美托咪啶經皮遞送裝置 |
| JP7343170B2 (ja) * | 2017-05-12 | 2023-09-12 | ボード オブ トラスティーズ オブ ザ サザン イリノイ ユニバーシティ オン ビハーフ オブ サザン イリノイ ユニバーシティ エドワーズビル | ３，４，５－三置換－１，２，４－トリアゾールおよび３，４，５－三置換－３－チオ－１，２，４－トリアゾール、ならびにそれらの使用 |
| CN107879979B (zh) * | 2017-10-27 | 2020-08-25 | 广东莱佛士制药技术有限公司 | 一种右美托咪定的制备方法 |
| CN114728982A (zh) | 2019-10-31 | 2022-07-08 | 逃逸生物有限公司 | 固体形式的s1p-受体调节剂 |
| WO2024240240A1 (zh) * | 2023-05-24 | 2024-11-28 | 江苏恩华药业股份有限公司 | 一种咪唑衍生物、中间体、制备方法及其应用 |
| KR20260023049A (ko) * | 2023-06-19 | 2026-02-20 | 지앙수 엔화 파마수티컬 컴퍼니 리미티드 | 치환된 이미다졸 유도체, 중간체, 제조 방법 및 이의 응용 |
| WO2025162114A1 (zh) * | 2024-02-04 | 2025-08-07 | 成都麻沸散医药科技有限公司 | 一种杂环化合物及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7312245A (nl) | 1973-09-06 | 1975-03-10 | Stamicarbon | Werkwijze voor het bereiden van alphamethylstyreen bevattende blokcopolymeren. |
| AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| JPH0733333B2 (ja) * | 1986-12-12 | 1995-04-12 | 三井石油化学工業株式会社 | 脳機能改善薬 |
| GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
| GB2256135B (en) | 1991-05-31 | 1995-01-18 | Orion Yhtymae Oy | Transdermal administration of 4-substituted imidazoles |
| GB9521680D0 (en) | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
| JP4783502B2 (ja) * | 1997-12-04 | 2011-09-28 | アラーガン、インコーポレイテッド | α２Ｂまたは２Ｂ／２Ｃアドレナリン受容体において作動剤様活性を示す置換イミダゾール誘導体 |
| JP4546589B2 (ja) * | 1998-04-23 | 2010-09-15 | 武田薬品工業株式会社 | ナフタレン誘導体 |
| WO1999054309A1 (en) * | 1998-04-23 | 1999-10-28 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
| PE20010781A1 (es) * | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
| JP4520012B2 (ja) * | 1999-10-22 | 2010-08-04 | 武田薬品工業株式会社 | １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類 |
| IL147921A0 (en) | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
| WO2005005394A2 (en) * | 2003-07-09 | 2005-01-20 | F.Hoffmann-La Roche Ag | Thiophenylaminoimidazolines as prostaglandin i2 antagonists |
| MXPA06002716A (es) * | 2003-09-12 | 2006-06-06 | Allergan Inc | Metodos y composiciones para el tratamiento de dolor y otras condiciones mediadas por adrenergicos de alfa-2. |
| NZ553341A (en) * | 2004-09-24 | 2010-11-26 | Allergan Inc | 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
-
2007
- 2007-01-17 WO PCT/EP2007/050441 patent/WO2007085556A2/en not_active Ceased
- 2007-01-17 CN CN2007800036567A patent/CN101374832B/zh not_active Expired - Fee Related
- 2007-01-17 ES ES07703939T patent/ES2338716T3/es active Active
- 2007-01-17 KR KR1020087020817A patent/KR101079914B1/ko not_active Expired - Fee Related
- 2007-01-17 BR BRPI0706759-3A patent/BRPI0706759A2/pt not_active IP Right Cessation
- 2007-01-17 CA CA2637308A patent/CA2637308C/en not_active Expired - Fee Related
- 2007-01-17 EP EP07703939A patent/EP1981880B1/en not_active Not-in-force
- 2007-01-17 RU RU2008130448/04A patent/RU2008130448A/ru not_active Application Discontinuation
- 2007-01-17 AT AT07703939T patent/ATE458732T1/de active
- 2007-01-17 AU AU2007209380A patent/AU2007209380B2/en not_active Ceased
- 2007-01-17 JP JP2008551759A patent/JP2009524616A/ja active Pending
- 2007-01-17 DE DE602007004949T patent/DE602007004949D1/de active Active
- 2007-01-19 US US11/655,539 patent/US8158668B2/en not_active Expired - Fee Related
- 2007-01-25 TW TW096102837A patent/TW200738645A/zh unknown
- 2007-01-26 AR ARP070100342A patent/AR059206A1/es unknown
-
2008
- 2008-07-17 IL IL192885A patent/IL192885A0/en unknown
- 2008-07-24 ZA ZA200806457A patent/ZA200806457B/xx unknown
- 2008-07-31 NO NO20083356A patent/NO20083356L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1981880A2 (en) | 2008-10-22 |
| DE602007004949D1 (de) | 2010-04-08 |
| RU2008130448A (ru) | 2010-03-10 |
| WO2007085556A2 (en) | 2007-08-02 |
| ES2338716T3 (es) | 2010-05-11 |
| AU2007209380A1 (en) | 2007-08-02 |
| CA2637308A1 (en) | 2007-08-02 |
| WO2007085556A3 (en) | 2007-10-04 |
| CN101374832A (zh) | 2009-02-25 |
| US20070197622A1 (en) | 2007-08-23 |
| BRPI0706759A2 (pt) | 2011-04-05 |
| KR101079914B1 (ko) | 2011-11-04 |
| TW200738645A (en) | 2007-10-16 |
| NO20083356L (no) | 2008-10-21 |
| AU2007209380B2 (en) | 2011-12-08 |
| US8158668B2 (en) | 2012-04-17 |
| CN101374832B (zh) | 2013-03-06 |
| JP2009524616A (ja) | 2009-07-02 |
| KR20080088658A (ko) | 2008-10-02 |
| CA2637308C (en) | 2014-02-25 |
| ATE458732T1 (de) | 2010-03-15 |
| IL192885A0 (en) | 2009-02-11 |
| ZA200806457B (en) | 2009-11-25 |
| EP1981880B1 (en) | 2010-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059206A1 (es) | Uso de derivados de 4-imidazol para trastornos del snc | |
| AR059207A1 (es) | Uso de derivados de 2-imidazol para el tratamiento de trastornos del snc | |
| CO6321133A2 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns | |
| AR059183A1 (es) | Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos | |
| TW200833685A (en) | Aminomethyl-4-imidazoles | |
| AR067772A1 (es) | Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos. | |
| AR085478A1 (es) | Derivados heterociclicos de amina | |
| AR063326A1 (es) | Aminometil-2-imidazoles, medicamentos que los contienen, metodo de preparacion, y usos para el tratamiento de trastornos asociados al sistema nervioso central | |
| CO6331336A2 (es) | Derivados de 4,5-dihidro-oxazol-2-ilo | |
| EA200800430A1 (ru) | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов | |
| AR086880A1 (es) | Derivados de morfolin-benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de las mismas para tratar enfermedades asociadas fundamentalmente al sistema nervioso central | |
| MX2017001096A (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo. | |
| BR112012011105A2 (pt) | derivados de oxazolina para tratamento de doenças do snc | |
| AR059182A1 (es) | Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos | |
| US20160137643A1 (en) | 1,7-naphthyridine derivatives | |
| MX2016013412A (es) | Derivados de morfolina-piridina. | |
| AR076979A1 (es) | 2- aminooxazolinas como ligandos de taar1 | |
| AR101339A1 (es) | Derivados del 6-amino-5,6,7,8-tetrahidronaftalen-2-ilo o del 3-aminocroman-7-ilo | |
| AR067675A1 (es) | 2-azetidinametanoaminas y 2-pirrolidinametanoaminas como ligandos de taar, un metodo para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento de trastornos del snc. | |
| RU2015118290A (ru) | Производные пиразина | |
| AR063811A1 (es) | 4-imidazoles sustituidos | |
| RU2007142023A (ru) | Пиперазин-замещенные бензотиофены для лечения психических расстройств | |
| TH106083A (th) | 2-อะมิโนออกซะโซลีนประดิษฐ์ใหม่เป็น taar1 ลิแกนด์ | |
| AR070007A1 (es) | Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| TH103563A (th) | ตัวปรับชนิดควบคู่ของ 5-HT2a และ D3 รีเซพเตอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |